WO2024240775 - PHARMACEUTICAL DOSAGE FORMS FOR PULSATILE RELEASE
National phase entry:
Publication Number
WO/2024/240775
Publication Date
28.11.2024
International Application No.
PCT/EP2024/063991
International Filing Date
21.05.2024
Title **
[English]
PHARMACEUTICAL DOSAGE FORMS FOR PULSATILE RELEASE
[French]
FORMES GALÉNIQUES PHARMACEUTIQUES POUR LIBÉRATION PULSATILE
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
PERTILE, Marisa
CEREA, Matteo
FOPPOLI, Anastasia
GAZZANIGA, Andrea
MOUTAHARRIK, Saliha
Priority Data
23175449.0
25.05.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2623 | |
| EPO | Filing, Examination, Granting | 18770 | |
| Japan | Filing, Examination, Granting | 2819 | |
| South Korea | Filing, Examination, Granting | 3529 | |
| USA | Filing, Examination, Granting | 7540 |
Total:
35,281
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to pharmaceutical dosage forms comprising a drug having a fast absorption in the gut, which is absorbed in distal intestinal tract including the colon, and for which pulsatile release is necessary to avoid the potential toxicity of the drug continuous absorption. In particular the invention is directed to a dosage form comprising a formulation in form of coated small units to deliver the active ingredient after a programmed time period following oral administration and processes of preparation thereof. In a preferred embodiment the drug is the iron chelator deferiprone.[French]
L'invention concerne des formes galéniques pharmaceutiques comprenant un médicament offrant une absorption rapide dans l'intestin, qui est absorbé dans le tractus intestinal distal comprenant le côlon, et pour lequel une libération pulsatile est nécessaire pour éviter la toxicité potentielle de l'absorption continue de médicament. En particulier, l'invention concerne une forme galénique comprenant une formulation sous la forme de petites unités enrobées destinées à délivrer le principe actif après une durée programmée suivant l'administration orale et des procédés de préparation de celle-ci. Dans un mode de réalisation préféré, le médicament est le chélateur du fer défériprone.